Adar Poonawalla Second In Children's Vaccine Race?
Adar Poonawalla remarked on thursday that his firm has invested over Rs 10,000 crore in the manufacture and delivery of the Covishield vaccination and that one of the major problems he has is dealing with public scrutiny and responsibility. He also stated that Covovax, another Covid-19 vaccine produced by his business, was selected for children for a variety of reasons. "We have sent statistics to the WHO for Covovax," he added, referring to the vaccine's availability. We picked Covovax as the vaccination for children for a variety of reasons. Vaccine stockpiles are no longer an impediment. We have adequate supplies to last a month. Covovax should be approved for kids as young as 2-3 years old by February.
While specialists are still waiting for WHO approval, it is being claimed that the vaccination, that is an indigenous, immobilised vaccine produced by Hyderabad-based Bharat Biotech, would be rolled out in stages for children, with the injections being accessible first for children with comorbidities. It's also been suggested that the vaccination might function in a similar way to how it works in adults.
While Covaxin has received emergency approval, the WHO has yet to formally approve it for usage. Only WHO-approved vaccinations are now recognized worldwide. However, the final clearance for children aged 2 to 18 is pending expert review as well as approval.
While specialists are still waiting for WHO approval, it is being claimed that the vaccination, that is an indigenous, immobilised vaccine produced by Hyderabad-based Bharat Biotech, would be rolled out in stages for children, with the injections being accessible first for children with comorbidities. It's also been suggested that the vaccination might function in a similar way to how it works in adults.
While Covaxin has received emergency approval, the WHO has yet to formally approve it for usage. Only WHO-approved vaccinations are now recognized worldwide. However, the final clearance for children aged 2 to 18 is pending expert review as well as approval.